Results 51 to 60 of about 5,903 (227)

Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study

Pharmaceutics
Fluoropyrimidines (FPs) are commonly prescribed in many cancer streams. The EMA and FDA-approved drug labels for FPs recommend genotyping the DPYD*2A (rs3918290), *13 (rs55886062), *HapB3 (rs56038477), alleles, and DPYD rs67376798 before treatment starts.
Xando Díaz-Villamarín, María Martínez-Pérez, María Teresa Nieto-Sánchez, Gabriela Ruiz-Tueros, Emilio Fernández-Varón, Alicia Torres-García, Beatriz González Astorga, Isabel Blancas, Antonio J. Iáñez, José Cabeza-Barrera, Rocío Morón   +10 more
doaj   +1 more source

Evaluation of the Expression Profile of Irinotecan-Induced Diarrhea in Patients with Colorectal Cancer

Pharmaceuticals, 2021
Irinotecan (CPT-11) is widely used for the treatment of unresectable colorectal cancer in combination with fluoropyrimidines, such as 5-fluorouracil and S-1.
Mashiro Okunaka, Daisuke Kano, Reiko Matsui, Toshikatsu Kawasaki, Yoshihiro Uesawa   +4 more
doaj   +1 more source

Control of Gemcitabine Activity With Blue and Red Light

Chemistry – A European Journal, EarlyView.
Treating cancer with chemotherapy is generally associated with many side effects, which can be addressed by selectively releasing the desired drugs with visible light. Sixteen new blue light‐activatable cytostatics were introduced, with the gemcitabine derivative exhibiting ideal properties.
Nils F. Kersten, Konstantin L. Stock, Marius Hyprath, Hannah Weisser, Timo Weinrich, Dieter Steinhilber, Alexander Heckel   +6 more
wiley   +1 more source

Novel Oligomeric Fluoropyrimidines and Their Efficacy for the Treatment of Colorectal Carcinoma Independent of p53 Mutation

, 2017
The treatment of advanced stage colorectal carcinoma (CRC) is rarely achieved with today’s standard of care, including 5-fluorouracil (5-FU). Resistance to 5-FU is unfortunately frequent in CRC partially due to the dependency 5-FU displays towards normal
Dominijanni, Anthony
core   +1 more source

Dihydropyrimidine Dehydrogenase Polymorphism c.2194G>A Screening Is a Useful Tool for Decreasing Gastrointestinal and Hematological Adverse Drug Reaction Risk in Fluoropyrimidine-Treated Patients

Current Issues in Molecular Biology
Although the risk of fluoropyrimidine toxicity may be decreased by identifying poor metabolizers with a preemptive dihydropyrimidine dehydrogenase (DPYD) test, following international standards, many patients with wild-type (WT) genotypes for classic ...
Alessio Ardizzone, Maria Bulzomì, Fabiola De Luca, Nicola Silvestris, Emanuela Esposito, Anna Paola Capra   +5 more
doaj   +1 more source

Head and Neck Lymph Node Metastases From Cancer of Unknown Primary: Outcomes From p16‐Guided Mucosal Radiotherapy

Head &Neck, EarlyView.
ABSTRACT Background The AJCC 8th edition distinguishes p16‐positive oropharyngeal head and neck carcinoma of unknown primary (HNCUP) due to its superior prognosis. However, standardized radiation volume guidelines are lacking. This study evaluates the safety of p16‐guided mucosal volume reduction.
Philippe Harris, Dhiya‐Eddine Mabrouki, Felix‐Phuc Nguyen‐Tan, Edith Filion, Olivier Ballivy, Brian O'Sullivan, Apostolos Christopoulos, Tareck Ayad, Louis Guertin, Eric Bissada, Paul Tabet, Denis Soulières, Antoine Desilets, Alexandre Pellan Cheng, Robert Doucet, Laurent Létourneau‐Guillon, Houda Bahig   +16 more
wiley   +1 more source

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI‐SAFRADJU‐2501)

International Journal of Cancer, EarlyView.
ABSTRACT The recommended adjuvant chemotherapy (adj‐ChT) regimen for resected biliary tract cancers (BTC) is capecitabine (Cape); yet, the recommendation is based on limited evidence. Although varied adj‐ChTs have been employed in practice, robust real‐world data is scarce. We conducted a national, multicenter, hospital‐based registry study to evaluate
Erman Akkus, Mehmet Kayaalp, Müzeyyen Aslı Ergözoğlu, Ilgın Koç Kuş, Doğan Bayram, Bilgeşah Kılıçtaş, Emel Ayvaz Güneyin, Ali Kalem, Haydar Temizyürek, Mehmet Mutlu Çatlı, Mehmet Sinan Akarca, Maral Martin Mıldanoğlu, Görkem Turhan, Mahmut Kara, Hacı Arak, Feyza Arslan Tan, Burak Paçacı, Berkay Yeşilyurt, Orhun Akdoğan, Emine Bihter Çetin, Selahattin Çelik, Fatma Keskin Uzundere, Elif Şahin, Zehra Sadak Öcal, Lamia Şeker Can, Bahadır Köylü, Mehmet Cem Fidan, Esmanur Kaplan Tüzün, Teoman Şakalar, Elif Sertesen Çamöz, Haydar Çağatay Yüksel, Onur Yazdan Balçık, Pınar Peker, Mehmet Yılmaz, Şeymanur Ala Enli, Erdem Kölemen, Sibel Oyucu Orhan, Yakup Düzköprü, Mustafa Ersoy, Tuğba Akın Telli, Mesut Yılmaz, Yusuf İlhan, Atila Yıldırım, Ramazan Coşar, Müslih Ürün, Arif Hakan Önder, Murat Araz, Ertuğrul Bayram, Havva Yeşil Çınkır, Ali Alkan, Mustafa Gürbüz, Nilüfer Avcı, Fatma Paksoy Türköz, İsmail Oğuz Kara, Fatih Köse, İlkay Tuğba Ünek, Ahmet Bilici, Öznur Bal, Şuayib Yalçın, Lorenza Rimassa, Hatime Arzu Yaşar   +60 more
wiley   +1 more source

HPV16-E7 Expression Causes Fluorodeoxyuridine-mediated Radiosensitization in SW620 Human Colon Cancer Cells

Neoplasia: An International Journal for Oncology Research, 1999
We have reported that HT29 colon cancer cells, which are radiosensitized by fluorodeoxyuridine (FdUrd), exhibit a greater increase in cyclin E—dependent kinase activity and progress further into S phase in the presence of FdUrd than do SW620 colon cancer
Michael D. Axelson, Mary A. Davis, Stephen P. Ethier, Theodore S. Lawrence   +3 more
doaj   +1 more source

Concomitant Use of Proton Pump Inhibitors and Survival Outcomes in Patients Receiving Adjuvant Chemotherapy for Stage III Colon Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Proton pump inhibitors (PPIs) are commonly prescribed in patients with cancer. Prior studies suggest concomitant PPI use may reduce the efficacy of oral capecitabine through impaired absorption, with no interaction expected with intravenous 5‐fluorouracil (5‐FU). Using the Australian Comprehensive Cancer Outcomes and Research Database (ACCORD),
Matthew Loft, Vinoja Ganeshanathan, Rachel Wong, Shehara Mendis, Matthew Croxford, Ian T. Jones, Grace Gard, Sue‐Anne McLachlan, Jeanne Tie, Lucy Gately, Peter Gibbs   +10 more
wiley   +1 more source

Thymidine Phosphorylase and Fluoropyrimidines Efficacy: A Jekyl and Hyde Story

, 2004
International audienceThymidine phosphorylase (TP) is markedly upregulated in many solid tumors such as colorectal, breast and kidney cancers. Because TP is identical to platelet-derived endothelial cell growth factor, this enzyme is believed to have ...
Evrard, Alexandre, Cuq, Pierre, Ciccolini, Joseph   +2 more
core   +1 more source